Combined neoadjuvant chemotherapy and immunotherapy in a hepatitis B virus-positive patient with locally advanced rectal adenocarcinoma: a case report and literature review.

ABSTRACT: Microsatellite-stable (MSS) rectal adenocarcinoma remains a therapeutic challenge, particularly in patients with complicating factors such as chronic hepatitis B virus (HBV) infection. Advances in immunotherapy, including immune checkpoint inhibitors (ICIs), have introduced new opportunities to improve the treatment outcomes in this subset, yet their application in HBV-positive cancer patients is less well understood. Here we report the case of a 46-year-old female with MSS locally advanced rectal adenocarcinoma and active HBV infection, successfully treated with cmFOLFOXIRI combined with camrelizumab as neoadjuvant therapy. The patient presented with a circumferential rectal mass, elevated tumor markers, and virological evidence of high HBV viral load, necessitating prophylactic antiviral

SUBMITTER: Li Q 

PROVIDER: S-EPMC12404937 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature